US government (USG) investment in global health R&D has delivered

$349.1 million to Georgia research institutions* 5,800+ new jobs for Georgia†

Georgia's top global health R&D institutions by USG funding*

<table>
<thead>
<tr>
<th>ORGANIZATION</th>
<th>FUNDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centers for Disease Control and Prevention (self-funding &amp; other agency transfers)</td>
<td>$129.8 million</td>
</tr>
<tr>
<td>Emory University</td>
<td>$147.8 million</td>
</tr>
<tr>
<td>University of Georgia</td>
<td>$61.0 million</td>
</tr>
<tr>
<td>Morehouse School of Medicine</td>
<td>$4.7 million</td>
</tr>
<tr>
<td>Georgia State University</td>
<td>$4.1 million</td>
</tr>
<tr>
<td>Augusta University College of Education</td>
<td>$745 thousand</td>
</tr>
<tr>
<td>Kennesaw State University</td>
<td>$481 thousand</td>
</tr>
</tbody>
</table>

Global health R&D at work in the Peach State

Emory University School of Medicine is supporting early stage clinical trials of a vaccine to prevent infection with chikungunya virus. Chikungunya is transmitted by mosquitoes and can cause persistent, debilitating joint pain. The virus, originating in Africa, arrived in the Caribbean several years ago and has since infected more than 2 million people in the Americas, including in the Florida Keys. If approved, the vaccine could be a powerful tool for protection.

Neglected diseases in Georgia‡

- HIV diagnoses: 24,140
- Tuberculosis cases: 3,299
- Malaria cases: 534
- West Nile cases: 190
- Zika cases: 110

Georgia industry in global health R&D

- Geovax: Atlanta
- Novartis: Duluth
- Pathens: Athens
- Sanofi: Forest Park
- Westat: Atlanta

Global health R&D is a smart investment for the United States §

- 89¢ of every dollar the USG invests in global health R&D stays within the United States, supporting the domestic economy.
- USG investment in global health R&D between 2007 and 2015 generated an estimated:
  - 200K new US jobs
  - $33 BILLION in US economic growth.

*Authors’ analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author’s analysis described above. See www.ghtcoalition.org for additional details.

‡Geovax: Atlanta
Novartis: Duluth
Pathens: Athens
Sanofi: Forest Park
Westat: Atlanta


* NTD: neglected tropical disease, VHF: viral hemorrhagic fever. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.